Best Stocks Under $2 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $2.00 (2 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. Western Copper & Gold NYSE:WRN$1.27 -0.08 (-5.93%) As of 08/18/2025 04:00 PM EasternWestern Copper & Gold Corp. operates as an exploration stage company, which engages in the acquisition, exploration, and future development of mineral resource properties. More about Western Copper & GoldMarket Capitalization$254.70 millionP/E Ratio-63.50Consensus RatingBuyConsensus Price Target$4.00 (+215.0% Upside)Volume326,345 sharesAverage Volume377,121 shares Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. Quince Therapeutics NASDAQ:QNCX$1.67 -0.02 (-1.18%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$1.68 +0.01 (+0.60%) As of 08/18/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about Quince TherapeuticsMarket Capitalization$90.78 millionP/E Ratio-1.53Consensus RatingBuyConsensus Price Target$8.14 (+387.6% Upside)Volume81,519 sharesAverage Volume216,887 shares3. Immunic NASDAQ:IMUX$0.98 +0.08 (+8.55%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$0.99 +0.01 (+1.38%) As of 05:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More about ImmunicMarket Capitalization$88.92 millionP/E Ratio-0.80Consensus RatingBuyConsensus Price Target$7.50 (+666.5% Upside)Volume1.28 million sharesAverage Volume1.18 million shares4. Mereo BioPharma Group NASDAQ:MREO$1.68 -0.06 (-3.45%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$1.71 +0.03 (+1.79%) As of 08/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. More about Mereo BioPharma GroupMarket Capitalization$276.66 millionP/E Ratio-24.00Consensus RatingBuyConsensus Price Target$7.20 (+328.6% Upside)Volume743,669 sharesAverage Volume1.70 million shares5. FibroBiologics NASDAQ:FBLG$0.62 +0.04 (+7.62%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$0.62 +0.00 (+0.29%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. More about FibroBiologicsMarket Capitalization$24.02 millionP/E Ratio-1.71Consensus RatingBuyConsensus Price Target$13.00 (+2,006.3% Upside)Volume360,540 sharesAverage Volume496,892 shares6. Stardust Power NASDAQ:SDST$0.41 +0.00 (+0.89%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$0.41 0.00 (0.00%) As of 05:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stardust Power Inc is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.Market Capitalization$24.71 millionP/E Ratio-0.73Consensus RatingBuyConsensus Price Target$5.11 (+1,147.0% Upside)Volume853,158 sharesAverage Volume3.49 million shares7. FiscalNote NYSE:NOTE$0.52 -0.01 (-0.96%) Closing price 08/18/2025 03:59 PM EasternExtended Trading$0.52 +0.01 (+0.97%) As of 08/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FiscalNote Holdings, Inc operates as technology company North America, Europe, Australia, and Asia. It combines artificial intelligence technology, machine learning, and other technologies with analytics, workflow tools, and expert research. More about FiscalNoteMarket Capitalization$82.59 millionP/E Ratio-1.62Consensus RatingBuyConsensus Price Target$2.44 (+371.5% Upside)Volume1.23 million sharesAverage Volume2.92 million shares8. Ur Energy NYSEAMERICAN:URG$1.29 +0.11 (+9.32%) Closing price 08/18/2025 04:10 PM EasternExtended Trading$1.28 -0.01 (-0.39%) As of 05:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur EnergyMarket Capitalization$430.50 millionP/E Ratio-7.59Consensus RatingBuyConsensus Price Target$2.48 (+91.9% Upside)Volume7.85 million sharesAverage Volume4.02 million shares9. Ovid Therapeutics NASDAQ:OVID$0.93 -0.04 (-4.12%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$0.94 +0.01 (+1.61%) As of 05:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More about Ovid TherapeuticsMarket Capitalization$68.98 millionP/E Ratio-1.75Consensus RatingBuyConsensus Price Target$3.10 (+233.3% Upside)Volume1.88 million sharesAverage Volume1.75 million shares10. Context Therapeutics NASDAQ:CNTX$0.87 +0.08 (+10.64%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$0.94 +0.07 (+7.47%) As of 05:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context TherapeuticsMarket Capitalization$70.53 millionP/E Ratio-2.42Consensus RatingBuyConsensus Price Target$5.25 (+503.4% Upside)Volume564,552 sharesAverage Volume145,626 shares11. Biomea Fusion NASDAQ:BMEA$1.74 +0.01 (+0.58%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$1.73 -0.01 (-0.57%) As of 04:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. More about Biomea FusionMarket Capitalization$102.95 millionP/E Ratio-0.57Consensus RatingBuyConsensus Price Target$16.80 (+865.5% Upside)Volume457,823 sharesAverage Volume772,904 shares12. Zura Bio NASDAQ:ZURA$1.74 +0.08 (+4.82%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$1.75 +0.01 (+0.57%) As of 08/18/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. More about Zura BioMarket Capitalization$113.50 millionP/E Ratio-2.49Consensus RatingBuyConsensus Price Target$14.17 (+714.2% Upside)Volume701,712 sharesAverage Volume369,716 shares13. Reviva Pharmaceuticals NASDAQ:RVPH$0.52 -0.02 (-3.85%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$0.53 +0.01 (+2.27%) As of 05:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva PharmaceuticalsMarket Capitalization$25.92 millionP/E Ratio-0.80Consensus RatingBuyConsensus Price Target$7.17 (+1,280.3% Upside)Volume3.48 million sharesAverage Volume2.82 million shares14. Aclaris Therapeutics NASDAQ:ACRS$1.85 -0.02 (-1.07%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$1.82 -0.03 (-1.62%) As of 08/18/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. More about Aclaris TherapeuticsMarket Capitalization$202.58 millionP/E Ratio-1.35Consensus RatingBuyConsensus Price Target$8.71 (+371.0% Upside)Volume1.14 million sharesAverage Volume1.47 million shares15. Autolus Therapeutics NASDAQ:AUTL$1.88 +0.10 (+5.62%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$1.88 +0.00 (+0.21%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. More about Autolus TherapeuticsMarket Capitalization$473.73 millionP/E Ratio-2.24Consensus RatingBuyConsensus Price Target$9.12 (+385.1% Upside)Volume3.77 million sharesAverage Volume2.57 million shares16. Ceragon Networks NASDAQ:CRNT$1.93 +0.01 (+0.52%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$2.00 +0.07 (+3.37%) As of 04:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ceragon Networks Ltd., together with its subsidiaries, provides wireless transport solutions for cellular operators and other wireless service providers in North America, Europe, Africa, the Asia Pacific, the Middle East, India, and Latin America. More about Ceragon NetworksMarket Capitalization$170.74 millionP/E Ratio12.06Consensus RatingBuyConsensus Price Target$5.30 (+174.6% Upside)Volume686,461 sharesAverage Volume1.07 million shares17. Lineage Cell Therapeutics NYSEAMERICAN:LCTX$1.28 +0.08 (+6.67%) Closing price 08/18/2025 04:10 PM EasternExtended Trading$1.22 -0.06 (-5.08%) As of 05:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. More about Lineage Cell TherapeuticsMarket Capitalization$274.03 millionP/E Ratio-7.11Consensus RatingBuyConsensus Price Target$4.20 (+228.1% Upside)Volume1.95 million sharesAverage Volume1.71 million shares18. Adicet Bio NASDAQ:ACET$0.72 +0.07 (+10.69%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$0.72 0.00 (-0.41%) As of 04:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. More about Adicet BioMarket Capitalization$54.53 millionP/E Ratio-0.55Consensus RatingBuyConsensus Price Target$6.00 (+727.6% Upside)Volume922,353 sharesAverage Volume556,952 shares19. InflaRx NASDAQ:IFRX$0.91 +0.05 (+5.74%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$0.92 +0.01 (+1.27%) As of 05:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. More about InflaRxMarket Capitalization$57.93 millionP/E Ratio-1.14Consensus RatingBuyConsensus Price Target$6.60 (+623.4% Upside)Volume125,767 sharesAverage Volume210,582 shares20. Lucid Diagnostics NASDAQ:LUCD$1.02 0.00 (0.00%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$1.02 +0.00 (+0.49%) As of 08/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. More about Lucid DiagnosticsMarket Capitalization$110.65 millionP/E Ratio-0.86Consensus RatingBuyConsensus Price Target$3.55 (+248.0% Upside)Volume677,614 sharesAverage Volume704,205 shares21. Cabaletta Bio NASDAQ:CABA$1.77 +0.06 (+3.51%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$1.77 0.00 (0.00%) As of 05:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. More about Cabaletta BioMarket Capitalization$156.41 millionP/E Ratio-0.65Consensus RatingBuyConsensus Price Target$14.43 (+715.2% Upside)Volume1.96 million sharesAverage Volume1.36 million shares22. Gain Therapeutics NASDAQ:GANX$1.77 +0.04 (+2.31%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$1.78 +0.00 (+0.28%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. More about Gain TherapeuticsMarket Capitalization$62.19 millionP/E Ratio-2.81Consensus RatingBuyConsensus Price Target$7.80 (+340.7% Upside)Volume877,603 sharesAverage Volume307,766 shares23. TScan Therapeutics NASDAQ:TCRX$1.79 -0.01 (-0.56%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$1.79 0.00 (0.00%) As of 08/18/2025 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. More about TScan TherapeuticsMarket Capitalization$101.86 millionP/E Ratio-1.64Consensus RatingBuyConsensus Price Target$7.80 (+335.8% Upside)Volume103,935 sharesAverage Volume267,067 shares24. Humacyte NASDAQ:HUMA$1.80 -0.08 (-4.26%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$1.85 +0.05 (+3.00%) As of 04:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. More about HumacyteMarket Capitalization$291.62 millionP/E Ratio-4.00Consensus RatingBuyConsensus Price Target$10.64 (+491.3% Upside)Volume3.71 million sharesAverage Volume6.20 million shares25. Bitfarms NASDAQ:BITF$1.38 +0.12 (+9.52%) Closing price 08/18/2025 04:00 PM EasternExtended Trading$1.39 +0.01 (+0.65%) As of 05:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bitfarms Ltd. engages in the mining of cryptocurrency coins and tokens in Canada, the United States, Paraguay, and Argentina. More about BitfarmsMarket Capitalization$702.51 millionP/E Ratio-8.12Consensus RatingBuyConsensus Price Target$3.95 (+186.2% Upside)Volume57.58 million sharesAverage Volume29.63 million shares More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Grab Holdings: Get a Grip Now—Explosive Upside Brewing Is Whirlpool A Screamin’ Buy in 2025? Signs Say Yes Why Datadog Is the AI Infrastructure Firm to Watch Out For Rocket Stock Just Broke Out, But EPS Growth Still Isn't Priced In Buffett Makes Big Moves Outside of UNH: A Buy and Sell Breakdown Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access